Treprostinil

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Treprostinil is a synthetic prostacyclin (IP-receptor) analog already established for treating pulmonary arterial hypertension (PAH). This Evidence Pack screened 10 TxGNN-predicted indications; the two most credible predictions — connective tissue disease-associated PAH (CTD-PAH) and congenital heart disease-associated PAH (CHD-PAH) — are well supported (L1/L2 evidence, including a subgroup RCT and a direct treprostinil Phase 2 trial), while 7 of the 10 predictions (e.g., hypotrichosis, congenital malformation syndromes) have zero supporting trials or literature and are most likely knowledge-graph noise.

Quick Overview

(Featured candidate: highest-evidence prediction, CTD-associated PAH)

Item	Content
Original Indication	Not stated in regulatory data (treprostinil is a marketed prostacyclin analog whose core approved use, per the evidence context, is idiopathic/heritable PAH)
Predicted New Indication	Pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH)
TxGNN Prediction Score	99.55%
Evidence Level	L1
US Market Status	✗ Not Marketed (0 licenses on file)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails (applies to CTD-PAH and CHD-PAH only — see full ranking below)

All 10 Predicted Indications (Full Ranking)

Rank	Predicted Indication	TxGNN Score	Evidence Level	Decision Stage	Recommendation
1	Pulmonary arteriovenous malformation	99.70%	L5	S0	Hold
2	PAH associated with congenital heart disease (CHD-PAH)	99.60%	L2	S2	Proceed with Guardrails
3	PAH associated with chronic hemolytic anemia	99.55%	L5	S0	Hold
4	PAH associated with schistosomiasis	99.55%	L5	S0	Hold
5	PAH associated with connective tissue disease (CTD-PAH)	99.55%	L1	S3	Proceed with Guardrails
6	PAH associated with HIV infection	99.55%	L3	S1	Research Question
7	Hypotrichosis simplex of the scalp	99.48%	L5	S0	Hold
8	Congenital hypotrichosis milia	99.30%	L5	S0	Hold
9	Malformation syndrome with odontal/periodontal component	99.21%	L5	S0	Hold
10	Ambras type hypertrichosis universalis congenita	99.17%	L5	S0	Hold

Why is This Prediction Reasonable?

Treprostinil is a stable synthetic analog of prostacyclin (PGI2). It activates the IP receptor on pulmonary vascular smooth muscle and platelets, producing pulmonary vasodilation, inhibition of platelet aggregation, and anti-proliferative effects that counteract vascular remodeling. This mechanism is the pharmacological basis for its established use in PAH (WHO Group 1).

CTD-PAH, CHD-PAH, and HIV-PAH are all recognized WHO Group 1 PAH subtypes that share the same core pulmonary vascular remodeling pathophysiology as idiopathic PAH — the population in which treprostinil’s efficacy is best established. This shared mechanism explains why the CTD-PAH prediction is backed by a dedicated subgroup RCT (PMID 15302727) and why a Phase 2 trial of IV treprostinil was specifically run in CHD-PAH neonates (NCT02261883). PAH associated with chronic hemolytic anemia and schistosomiasis fall under WHO Group 5/1 with more heterogeneous, less prostacyclin-responsive pathophysiology, which is consistent with the complete absence of supporting trials or literature for those two candidates.

In contrast, predictions such as hypotrichosis simplex, congenital hypotrichosis milia, Ambras-type hypertrichosis, and the periodontal/odontal malformation syndrome have no mechanistic link to vascular smooth muscle or platelet biology. For the periodontal-component prediction, all 20 retrieved literature hits discuss periodontitis pathophysiology with no mention of treprostinil or prostacyclin pathways — a strong indicator of keyword-coincidence false positives in the knowledge graph rather than genuine drug-disease relevance.

Clinical Trial Evidence

CHD-Associated PAH (Rank 2, L2)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02261883	Phase 2	Terminated	42	IV Remodulin (treprostinil) as add-on therapy in neonates with CHD-related persistent pulmonary hypertension; direct drug evidence but trial was terminated early.
NCT01383083	N/A	Unknown	42	Iloprost (a related prostacyclin analog, not treprostinil) in adult Eisenmenger-physiology PAH-CHD; indirect class-level support only.

CTD-Associated PAH (Rank 5, L1)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02663895	Phase 2	Completed	12	Oral treprostinil in systemic sclerosis; primary endpoint was calcinosis reduction, not PAH itself — indirect safety/tolerability evidence in the same CTD population.

HIV-Associated PAH (Rank 6, L3)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00494533	Phase 4	Terminated	45	RCT of IV Remodulin (treprostinil) vs placebo in PAH including HIV- and collagen vascular disease-associated subgroups; terminated, HIV-specific enrollment criteria unconfirmed.

All Other Predictions (Ranks 1, 3, 4, 7, 8, 9, 10)

Currently no related clinical trials registered.

Literature Evidence

CHD-Associated PAH (Rank 2)

PMID	Year	Type	Journal	Key Findings
29436381	2018	Cohort	Heart	Subcutaneous treprostinil in adult CHD-PAH: efficacy/safety after 12 months of treatment — most directly relevant evidence.
35000655	2022	Case Report	Cardiology in the Young	Trisomy 21 + CHD-PAH: hemodynamics and exercise capacity improved after switching from oral selexipag to SC treprostinil.
23890862	2013	Cohort	Int J Cardiol	Long-term continuous prostacyclin therapy (incl. treprostinil) in adults with CHD-PAH.
18473715	2008	Review	Expert Opin Pharmacother	Treprostinil for PH treatment, including CHD-associated etiology.
22872790	2012	Review	Clin Med Insights Circ Respir Pulm Med	Clinical utility of treprostinil across PAH etiologies including CHD.
35412560	2022	Review	JAMA	General PAH diagnosis/treatment review (background).
21852894	2009	Cohort	Prog Pediatr Cardiol	Non-CHD pediatric PAH context — background/comparator only.

CTD-Associated PAH (Rank 5)

PMID	Year	Type	Journal	Key Findings
15302727	2004	RCT (subgroup)	Chest	SC treprostinil efficacy/safety specifically in CTD-associated PAH — strongest direct evidence.
11897647	2002	RCT	Am J Respir Crit Care Med	Foundational double-blind, placebo-controlled RCT of continuous SC treprostinil in PAH (includes CTD subgroup).
38378970	2024	Systematic Review/Meta-analysis	Intern Emerg Med	CTD-PAH treatment outcomes across RCT subgroup/post-hoc analyses.
34462153	2021	Retrospective Multicenter	Rev Med Interne	Characteristics/outcomes of CTD-PAH patients treated with prostanoids.
37765060	2023	Review	Pharmaceuticals	Recent advances in CTD-PAH treatment.
41594679	2026	Review	Biomolecules	Current therapeutic strategies and future prospects in CTD-PAH.
40005302	2025	Case Report	Medicina	Inhaled treprostinil efficacy in systemic sclerosis-associated PH refractory to IV epoprostenol.
16218473	2005	Review	Lupus	PAH associated with connective tissue diseases — pathophysiology overview.
22621693	2012	Review	Drugs	Treatment of PAH in connective tissue disease.
35412560	2022	Review	JAMA	General PAH diagnosis/treatment review (background).

HIV-Associated PAH (Rank 6)

PMID	Year	Type	Journal	Key Findings
14720012	2003	Review	Am J Respir Med	Prostanoids for PAH, including HIV-associated subgroup.
18473715	2008	Review	Expert Opin Pharmacother	Treprostinil for PH, including HIV-associated etiology.
18260882	2007	Review	Kardiologiia	Prostanoids in PAH treatment across etiologies including HIV infection.

Low-Confidence Predictions (Ranks 1, 3, 4, 7, 8, 9, 10)

Currently no related literature available, except the malformation-syndrome candidate (Rank 9), where 20 literature hits were retrieved — all exclusively about periodontitis pathophysiology/treatment with no mention of treprostinil or prostacyclin pathways. This is assessed as keyword-coincidence noise, not genuine supporting evidence.

US Market Information

Treprostinil currently has 0 marketing licenses on file and is not marketed in this jurisdiction. No approved-indication label text is available for comparison against the predicted indications.

Safety Considerations

Please refer to the package insert for safety information.

Critical data gap: Detailed labeled warnings and contraindications (TFDA label PDF) have not yet been retrieved (Blocking severity). This gap must be closed before any indication in this pack can proceed past initial safety screening (S1).

Conclusion and Next Steps

Decision: Proceed with Guardrails (for CTD-PAH and CHD-PAH only) / Hold (for the remaining 7 low-evidence candidates)

Rationale:

CTD-PAH is backed by a dedicated subgroup RCT plus a 2024 systematic review/meta-analysis and mechanistically fits treprostinil’s established WHO Group 1 PAH indication (L1).
CHD-PAH has a direct (though terminated) Phase 2 treprostinil trial and coherent mechanistic rationale (L2).
HIV-PAH has only review-level, non-drug-specific literature (L3) — flagged for further research rather than progression.
The remaining 6 candidates (pulmonary arteriovenous malformation, hemolytic anemia-PAH, schistosomiasis-PAH, hypotrichosis simplex, congenital hypotrichosis milia, Ambras hypertrichosis) and the periodontal malformation-syndrome candidate have no genuine supporting evidence and should not be pursued.

To proceed, the following is needed:

Retrieve and parse the TFDA/manufacturer package insert for full warnings, contraindications, and DDI data (Blocking gap, DG001)
Confirm original approved indication and MOA directly from DrugBank/regulatory source rather than inference (DG002)
For CHD-PAH: obtain termination reason and any interim data from NCT02261883
For HIV-PAH: verify actual enrollment criteria of NCT00494533 to confirm HIV-specific subgroup data exists
Route/formulation compatibility assessment (SC/IV/inhaled/oral) against each target population’s clinical practicality
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.